Ipsen (IPSEF.PK) said its partner Teijin obtained manufacturing and marketing approval from the Japan's Ministry of Health, Labour and Welfare for Somatuline 60/90/120 mg for s.c. injection (lanreotide acetate). In Japan, Somatuline is indicated for the treatment of growth hormone and IGF-I (somatomedin-C) hypersecretion and related symptoms in acromegaly and pituitary gigantism.
The company noted that Somatuline will be available in a new enhanced presentation with a pre-filled syringe that does not need reconstitution and with a retractable needle that improves safety for caregivers.
Click here to receive FREE breaking news email alerts for Ipsen Promesses and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com